| 1. |
- Attwood, Misty M., et al.
(författare)
-
Orphan Drugs and Their Impact on Pharmaceutical Development
- 2018
-
Ingår i: TIPS - Trends in Pharmacological Sciences. - : Elsevier BV. - 0165-6147 .- 1873-3735. ; 39:6, s. 525-535
-
Forskningsöversikt (refereegranskat)abstract
- High levels of productivity, with an increasing number of approvals for new molecular entities (NMEs) by the FDA during the past decade, have coincided with the emergence of innovative drugs for treatments of rare diseases that have utilized the FDA orphan drug program. Since 2000, NMEs with orphan designation encompass a significant portion of approved drugs and constitute about 80% of the approved drugs that have established novel human genome-encoded products in recent years. Biological approvals are also expanding, with 40% of the approved biological agents having orphan designation. This trend illustrates a pivot within the pharmaceutical industry: from research programs that focus on canonical blockbuster indications and targets, towards the establishment of new treatments for rare and difficult to treat diseases.
|
|
| 2. |
|
|
| 3. |
- Banerjee, Debarshi, et al.
(författare)
-
Adding nanotechnology to the metastasis treatment arsenal
- 2019
-
Ingår i: TIPS - Trends in Pharmacological Sciences. - Cambridge, Massachusets : Elsevier. - 0165-6147 .- 1873-3735. ; 40:6, s. 403-418
-
Forskningsöversikt (refereegranskat)abstract
- Metastasis is a major cause of cancer-related mortality, accounting for 90% of cancer deaths. The explosive growth of cancer biology research has revealed new mechanistic network information and pathways that promote metastasis. Consequently, a large number of antitumor agents have been developed and tested for their antimetastatic efficacy. Despite their exciting cytotoxic effects on tumor cells in vitro and antitumor activities in preclinical studies in vivo, only a few have shown potent antimetastatic activities in clinical trials. In this review, we provide a brief overview of current antimetastatic strategies that show clinical efficacy and review nanotechnology-based approaches that are currently being incorporated into these therapies to mitigate challenges associated with treating cancer metastasis.
|
|
| 4. |
- Blennow, Kaj, 1958, et al.
(författare)
-
Amyloid biomarkers in Alzheimer's disease.
- 2015
-
Ingår i: Trends in pharmacological sciences. - : Elsevier BV. - 1873-3735 .- 0165-6147. ; 36:5, s. 297-309
-
Tidskriftsartikel (refereegranskat)abstract
- Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development. Biomarkers to monitor Aβ metabolism and aggregation directly in patients are important for further detailed study of the involvement of Aβ in disease pathogenesis and to monitor the biochemical effect of drugs targeting Aβ in clinical trials. Furthermore, if anti-Aβ disease-modifying drugs prove to be effective clinically, amyloid biomarkers will be of special value in the clinic to identify patients with brain amyloid deposition at risk for progression to AD dementia, to enable initiation of treatment before neurodegeneration is too severe, and to monitor drug effects on Aβ metabolism or pathology to guide dosage. Two types of amyloid biomarker have been developed: Aβ-binding ligands for use in positron emission tomography (PET) and assays to measure Aβ42 in cerebrospinal fluid (CSF). In this review, we present the rationales behind these biomarkers and compare their ability to measure Aβ plaque load in the brain. We also review possible shortcomings and the need of standardization of both biomarkers, as well as their implementation in the clinic.
|
|
| 5. |
|
|
| 6. |
- Epstein, David H., et al.
(författare)
-
Science-Based Actions Can Help Address the Opioid Crisis
- 2018
-
Ingår i: TIPS - Trends in Pharmacological Sciences. - : ELSEVIER SCIENCE LONDON. - 0165-6147 .- 1873-3735. ; 39:11, s. 911-916
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The epidemic of addiction and over-dose is real. Addiction among pain patients accounts for only a small proportion but a large number. Scientific opinion leaders can be most effective on two fronts, each relatively low-tech: dissemination and oversight of empirically established treatments, and promulgation of social-science-based strategies for population-level prevention.
|
|
| 7. |
- Ingeiman-Sundberg, M
(författare)
-
Interview with Magnus Ingelman-Sundberg
- 2015
-
Ingår i: Trends in pharmacological sciences. - : Elsevier BV. - 1873-3735 .- 0165-6147. ; 36:2, s. 65-67
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 8. |
- Jespers, Willem, et al.
(författare)
-
Structural Mapping of Adenosine Receptor Mutations : Ligand Binding and Signaling Mechanisms
- 2018
-
Ingår i: TIPS - Trends in Pharmacological Sciences. - : Elsevier BV. - 0165-6147 .- 1873-3735. ; 39:1, s. 75-89
-
Forskningsöversikt (refereegranskat)abstract
- The four adenosine receptors (ARs), A(1), A(2A), A(2B), and A(3), constitute a subfamily of G protein-coupled receptors (GPCRs) with exceptional foundations for structure-based ligand design. The vast amount of mutagenesis data, accumulated in the literature since the 1990s, has been recently supplemented with structural information, currently consisting of several inactive and active structures of the A(2A) and inactive conformations of the A(1) ARs. We provide the first integrated view of the pharmacological, biochemical, and structural data available for this receptor family, by mapping onto the relevant crystal structures all site-directed mutagenesis data, curated and deposited at the GPCR database (available through http://www.gpcrdb.org). This analysis provides novel insights into ligand binding, allosteric modulation, and signaling of the AR family.
|
|
| 9. |
|
|
| 10. |
- Lauschke, VM, et al.
(författare)
-
Precision Medicine and Rare Genetic Variants
- 2016
-
Ingår i: Trends in pharmacological sciences. - : Elsevier BV. - 1873-3735 .- 0165-6147. ; 37:2, s. 85-86
-
Tidskriftsartikel (refereegranskat)
|
|
